ConductScience.org, home

Library / Trial comparisons

Intervention Arm vs Usual Care: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.140.1170.168wilsonClinicalTrials.gov
Risk in group 20.1290.1230.134wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.0117-0.01260.0398newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.090.9041.32logClinicalTrials.gov
Odds ratio, group 1 over group 21.110.8891.38logClinicalTrials.gov
Number needed to harm, for one more participant with a serious adverse event on Intervention Arm than on Usual Care85.3from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: usual care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Intervention Arm
An alerted inpatient pharmacist or a designated study team member will bring the clopidogrel medication to the patient who has received a coronary stent. The patient will return home and receive IVR refill reminder calls.~Multifaceted Intervention with pharmacist and IVR: An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
99706EG000ClinicalTrials.gov
Group 2Usual Care
The sites will have no interaction with the study personnel. The investigators will use database information to compare with the intervention sites~Multifaceted Intervention with pharmacist and IVR: An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
1,78213,867EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, serious adverse eventsClinicalTrials.gov
Time frame12 months post PCI dischargeClinicalTrials.gov

Trial 8

FieldValueSource
TitleHybrid Effectiveness-Implementation Study to Improve Clopidogrel AdherenceClinicalTrials.gov
NCT numberNCT01609842ClinicalTrials.gov
PhasesNAClinicalTrials.gov
ConditionsCardiovascular Disease, Acute Coronary SyndromeClinicalTrials.gov
InterventionsMultifaceted Intervention with pharmacist and IVRClinicalTrials.gov
Lead sponsorVA Office of Research and DevelopmentClinicalTrials.gov
Results first posted2020-01-27ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT01609842?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.